KOSDAQ - Delayed Quote KRW

Chabiotech Co.,Ltd. (085660.KQ)

Compare
11,570.00
-300.00
(-2.53%)
At close: January 10 at 3:30:04 PM GMT+9
Currency in KRW All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,009,799,453.84
953,951,423.13
844,582,867.31
727,476,086.76
664,716,825.66
Cost of Revenue
743,720,437.78
677,579,504.84
640,028,451.46
510,836,756.65
473,787,272.28
Gross Profit
266,079,016.06
276,371,918.29
204,554,415.85
216,639,330.11
190,929,553.38
Operating Expense
304,263,793.45
285,797,108.60
251,630,486.44
208,924,246.27
193,019,737.39
Operating Income
-38,184,777.39
-9,425,190.31
-47,076,070.59
7,715,083.84
-2,090,184.01
Net Non Operating Interest Income Expense
-19,184,025.86
14,005,739.73
-12,021,055.31
-8,684,606.37
-12,905,009.96
Pretax Income
-4,906,246.42
3,187,927.56
-71,302,408.96
-10,032,603.76
-30,981,179.79
Tax Provision
2,534,364.28
8,747,841.21
-1,643,336.56
11,810,929.54
3,197,743.09
Net Income Common Stockholders
-2,600,072.25
-8,431,247.32
-47,542,787.80
-13,968,474.44
-18,658,191.06
Basic EPS
-46.00
-150.00
-845.00
-256.00
-355.00
Diluted EPS
-208.00
-175.00
-845.00
-256.00
-356.00
Basic Average Shares
56,197.82
56,208.32
56,263.65
54,564.35
52,558.29
Diluted Average Shares
99,337.40
48,178.56
56,263.65
54,564.35
52,410.65
Total Operating Income as Reported
-38,163,315.46
-9,567,468.72
-47,076,070.73
7,712,977.33
-2,446,838.47
Rent Expense Supplemental
3,017,927.75
2,689,014.40
2,020,318.08
1,670,545.93
1,040,782.99
Total Expenses
1,047,984,231.23
963,376,613.44
891,658,937.90
719,761,002.92
666,807,009.67
Net Income from Continuing & Discontinued Operation
-2,600,072.25
-8,431,247.32
-47,542,787.80
-13,968,474.44
-18,658,191.06
Normalized Income
-31,673,654.94
-8,545,091.85
-43,668,500.25
-198,285.07
-13,557,374.23
Interest Income
10,563,872.35
12,923,223.76
6,592,603.15
5,170,047.16
3,873,647.56
Interest Expense
32,049,306.71
29,100,774.81
20,867,654.87
14,533,618.77
14,919,209.64
Net Interest Income
-19,184,025.86
14,005,739.73
-12,021,055.31
-8,684,606.37
-12,905,009.96
EBIT
27,143,060.29
32,288,702.37
-50,434,754.09
4,501,015.01
-16,061,970.15
EBITDA
67,161,017.24
70,087,778.29
-17,914,988.32
32,363,480.48
9,379,589.99
Reconciled Cost of Revenue
743,720,437.78
677,579,504.84
640,028,451.46
510,836,756.65
473,787,272.28
Reconciled Depreciation
40,017,956.95
37,799,075.92
32,519,765.77
27,862,465.47
25,441,560.14
Net Income from Continuing Operation Net Minority Interest
-2,600,072.25
-8,431,247.32
-47,542,787.80
-13,968,474.44
-18,658,191.06
Total Unusual Items Excluding Goodwill
38,254,714.07
149,795.43
-3,965,686.39
-18,360,252.49
-6,801,089.11
Total Unusual Items
38,254,714.07
149,795.43
-3,965,686.39
-18,360,252.49
-6,801,089.11
Normalized EBITDA
28,906,303.17
69,937,982.86
-13,949,301.93
50,723,732.97
16,180,679.10
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
9,181,131.38
35,950.90
-91,398.84
-4,590,063.12
-1,700,272.28
12/31/2020 - 2/10/2009

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers